Abstract
Methotrexate has been a valuable drug in the management of severe generalized psoriasis for over 35 years as pointed out in the article by Gilbert et al<sup>1</sup>in this issue of theArchives. Gubner<sup>2</sup>described the benefit of aminopterin (precursor of methotrexate) in the clearing of psoriatic skin lesions See also p 889. in 1951 while using methotrexate to treat rheumatoid arthritis. This cancer chemotherapeutic drug became standard therapy for severe psoriasis from 1955 to 1972 despite its lack of approval by the Food and Drug Administration (FDA). In 1965, Roenigk et al<sup>3</sup>reported a new weekly dosage schedule of methotrexate for use in psoriasis. We found "a few minimal changes in hepatic function studies in eight of 45 psoriatics" receiving methotrexate. Since other authors were beginning to report methotrexate-induced hepatic injury, we cautioned that future followup studies were needed to determine the long-term effect of methotrexate
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
